The long-term effects of rosiglitazone on serum lipid concentrations and body weight.

Abstract

OBJECTIVE:

Although rosiglitazone, an insulin sensitizer, is known to have beneficial effects on high density lipoprotein cholesterol (HDL-C) concentrations and low density lipoprotein (LDL) particle size, it has unwanted effects on total cholesterol (TC) and LDL cholesterol (LDL-C) concentrations and body weight in some short-term studies. The aim of this study was to evaluate the long-term effects of rosiglitazone on serum lipid levels and body weight.

DESIGN:

Open labelled clinical study.

PATIENTS AND MEASUREMENTS:

We prospectively evaluated fasting serum glucose, haemoglobin A(1c) (HbA(1c)), lipid profiles and body weight at baseline and every 3 months after the use of rosiglitazone (4 mg/day) for 18 months in 202 type 2 diabetic patients.

RESULTS:

TC levels increased maximally at 3 months and decreased thereafter. However, overall, TC levels remained significantly higher at 18 months than those at baseline. LDL-C levels from the 3-month to the 12-month timepoint were significantly higher than those at baseline. However, after 15 months, LDL-C concentrations were not significantly different from basal LDL-C concentrations. HDL-C levels increased after the first 3 months and these levels were maintained. The increment of change in HDL-C was more prominent in patients with low basal HDL-C concentrations than in patients with high basal HDL-C concentrations. Body weight increased after the first 3 months and these levels were maintained.

CONCLUSIONS:

HDL-C and body weight increased and remained elevated for the duration of the study. There was an initial increase in LDL-C but this attenuated and by the end of the study was not significantly elevated above baseline levels.

• Authors: Wan Sub Shim, Mi Young Do, Soo Kyung Kim, Hae Jin Kim, Kyu Yeon Hur, Eun Seok Kang, Chul Woo Ahn, Sung Kil Lim, Hyun Chul Lee, Bong Soo Cha
• Journal: Clinical endocrinology (Clin Endocrinol (Oxf)) Vol. 65 Issue 4 Pg. 453-9 (Oct 2006) ISSN: 0300-0664 [Print] England
• PMID: 16984237 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Blood Glucose
• Cholesterol, HDL
• Cholesterol, LDL
• Glycated Hemoglobin A
• Hypoglycemic Agents
• Insulin
• Lipids
• Thiazolidinediones
• Triglycerides
• Rosiglitazone
• Cholesterol

Topics

• Adult
• Blood Glucose (metabolism)
• Body Mass Index
• Body Weight
• Cholesterol (blood)
• Cholesterol, HDL (blood)
• Cholesterol, LDL (blood)
• Diabetes Mellitus, Type 2 (blood, drug therapy)
• Female
• Glycated Hemoglobin (analysis)
• Humans
• Hypoglycemic Agents (therapeutic use)
• Insulin (blood)
• Lipids (blood)
• Male
• Middle Aged
• Prospective Studies
• Rosiglitazone
• Thiazolidinediones (therapeutic use)
• Time
• Triglycerides (blood)